The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Outpatient dosing of bispecific antibodies: what do clinicians need to consider?
At present, hospitalization is required during the initial step-up dosing of bispecific antibodies, limiting their administration to large specialist centers. Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, briefly outlines the factors that physicians will need to consider once outpatient dosing of these agents becomes widespread. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Consultancy, Honoraria, Research Funding; Janssen: Honoraria; BMS: Honoraria; AbbVie: Honoraria; Roche: Honoraria; University College London Hospitals NHS Foundation Trus: Current Employment. Gironella: Janssen: Consultancy, Honoraria; GSK: Consultancy.
